Assaying FVIII activity: One method is not enough, and never was

Haemophilia

Volumn 20, Issue 3, 2014, Pages 301-303

  Makris, M ^a,b   Peyvandi, F ^c  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b ROYAL HALLAMSHIRE HOSPITAL   (United Kingdom)

^c UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 9; BLOOD CLOTTING FACTOR CONCENTRATE; DESMOPRESSIN; RECOMBINANT BLOOD CLOTTING FACTOR 8;

BLOOD ANALYSIS; BLOOD CLOTTING FACTOR 8 ASSAY; BLOOD CLOTTING TEST; CHROMOGENIC FACTOR VIII ASSAY; CLINICAL LABORATORY; COST CONTROL; EDITORIAL; GENE MUTATION; HEMOPHILIA A; HUMAN; ONE STAGE CLOTTING ASSAY; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; PROTEIN CONTENT; TWO STAGE CLOTTING ASSAY; BIOSYNTHESIS; BLOOD; HEMARTHROSIS; METABOLISM;

FACTOR VIII; HEMARTHROSIS; HEMOPHILIA A; HUMANS;

EID: 84898630459     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/hae.12446     Document Type: Editorial

References (11)

1. UK National External Quality Assessment Scheme for Blood Coagulation, 2013: Survey 203
2. Rodgers SE, Duncan EM, Barbulescu DM, Quinn DM, Lloyd JV. In vitro kinetics of factor VIII activity in patients with mild haemophilia A and a discrepancy between one-stage and two-stage factor VIII assay results. Br J Haematol 2006; 136: 138-45.
3. Duncan EM, Duncan BM, Tunbridge LJ, Lloyd JV. Familial discrepancy between the one-stage and two-stage FVIII methods in a subgroup of patients with haemophilia A. Br J Haematol 1994; 87: 846-8.
4. Cid AR, Calabuig M, Cortina V et al. One-stage and chromogenic FVIII: C assay discrepancy in mild haemophilia A and the relationship with the mutation and bleeding phenotype. Haemophilia 2008; 14: 1049-54.
5. Bowyer AE, van Veen JJ, Goodeve AC, Kitchen S, Makris M. Specific and global coagulation assays in the diagnosis of discrepant mild haemophilia A. Haematologica 2013; 98: 1980-7.
6. Lyall H, Hill M, Westby J, Grimley C, Dolan G. Tyr346Cys mutation results in FVIII: C assay discrepancy and a normal phenotype - is this mild haemophilia A. Haemophilia 2008; 14: 78-80.
7. Bowyer AE, Goodeve AC, Liesner R, Mumford AD, Kitchen S, Makris M. P. Tyr365Cys change in FVIII: haemophilia A, but not as we know it. Br J Haematol 2011; 154: 618-25.
8. Barrowcliffe TW, Hubbard AR, Kitchen S. Standards and monitoring treatment. Haemophilia 2012; 18(Suppl. 4): 61-5.
9. Christiansen MLS, Balling KW, Persson E et al. Functional characteristics of N8, a new recombinant FVIII. Haemophilia 2010; 16: 878-87.
10. Pahl S, Schwaab R, Oldenburg J, Herbiniaux U, Aburubaiha Z. Characterisation of FVIII variants of the B-domain regarding their biological activity. Haemophilia 2010; 16(Suppl. 4): 95.
11. Hubbard AR, Dodt J, Lee T et al. Recommendations on the potency labelling of factor VIII and factor IX concentrates. J Thromb Haemost 2013; 11: 988-99.